A phase II, randomized, double-blind, placebo-controlled trial of Trans-sodium crocetinate in hemorrhagic and ischemic stroke patients

Trial Profile

A phase II, randomized, double-blind, placebo-controlled trial of Trans-sodium crocetinate in hemorrhagic and ischemic stroke patients

Planning
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2018

At a glance

  • Drugs Transcrocetinate sodium (Primary)
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms PHAST-TSC
  • Most Recent Events

    • 01 Feb 2018 According to a Diffusion Pharmaceuticals media release, this study will be conducted in co-operation with the University of California Los Angeles (UCLA) and the University of Virginia (UVA).
    • 29 Jan 2018 New trial record
    • 24 Jan 2018 According to a Diffusion Pharmaceuticals media release, the design and rationale for the trial will be presented at the International Stroke Conference 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top